Copyright
©The Author(s) 2019.
World J Diabetes. Nov 15, 2019; 10(11): 517-533
Published online Nov 15, 2019. doi: 10.4239/wjd.v10.i11.517
Published online Nov 15, 2019. doi: 10.4239/wjd.v10.i11.517
Table 1 Clinical characteristics of type 2 diabetic individuals with different patterns of chronic kidney disease
Parameter | CKD- (n = 89) | NA-CKD (n = 111) | A-CKD– (n = 87) | A-CKD+ (n = 73) |
General clinical parameters | ||||
Sex, M/F, n (%) | 20/69 | 13/98 | 45/42 | 22/51 |
22.5/77.5 | 11.7/88.3afh | 51.9/48.1ch | 30.1/69.9e | |
Age, yr | 64 (58; 67) | 68 (64; 73)bfi | 63 (59; 68)i | 67 (61; 77)ae |
BMI, kg/m2 | 33.4 (28.7; 36.9) | 32.6 (29.4; 37.2) | 33.6 (30.1; 38.2) | 33.4 (30.0; 36.8) |
WHR | 0.97 (0.94; 1.03) | 0.94 (0.89; 0.99)fh | 1.04 (0.97; 1.11)a | 0.98 (0.95; 1.07) |
Smoking, n (%) | 7 (7.9) | 6 (5.4) | 18 (20.9)a | 3 (4.1) |
Diabetes duration, yr | 15 (12; 19) | 18 (15; 25)cd | 15 (13; 20) | 18 (14; 22)a |
Diabetic complications and comorbidities | ||||
Diabetic retinopathy, n (%) | 62 (69.7) | 74 (66.7) | 65 (74.7) | 57 (78.1) |
Arterial hypertension, n (%) | 85 (95.5) | 111 (100) | 87 (98.9) | 73 (100) |
Coronary artery disease, n (%) | 41 (46.1) | 58 (52.3) | 46 (52.9) | 41 (56.2) |
Myocardial infarction in anamnesis, n (%) | 7 (7.9) | 19 (17.1) | 20 (23.0)b | 17 (23.3)b |
Chronic heart failure (NYHA class III-IV), n (%) | 5 (5.6) | 7 (6.3) | 11 (12.6) | 4 (5.5) |
Carotid atherosclerosis, n (%) | 15 (16.9) | 51 (45.9)c | 33 (37.9)a | 40 (54.8)c |
Cerebrovascular event in anamnesis, n (%) | 6 (6.7) | 13 (11.7)a | 5 (5.8) | 11 (15.1)a |
Peripheral artery disease, n (%) | 60 (67.4) | 84 (75.7) | 59 (67.8) | 57 (78.1)a |
Treatment | ||||
Metformin, n (%) | 61 (68.5) | 64 (57.7) | 56 (64.4) | 43 (58.9) |
Sulfonylurea, n (%) | 29 (32.6) | 31 (27.9)g | 21 (24.1) | 10 (13.7)b |
Insulin, n (%) | 74 (83.1) | 94 (84.7)g | 76 (87.5) | 70 (95.9)a |
Duration of insulin therapy, yr | 6 (4; 10) | 10 (7; 13)cf | 6 (3; 10) | 8 (3; 11) |
Daily insulin dose, IU | 52 (36; 72) | 46 (34; 62)g | 56 (40; 78) | 60 (42; 74) |
Daily insulin dose, IU/kg | 0.60 (0.40; 0.80) | 0.55 (0.40; 0.70) | 0.60 (0.40; 0.80) | 0.63 (0.45; 0.90) |
RAS blockers, n (%) | 67 (75.3) | 93 (83.8) | 69 (79.3) | 61 (83.6) |
Diuretics, n (%) | 36 (40.4) | 73 (65.8)adg | 38 (43.7) | 35 (47.9) |
Calcium channel blockers, n (%) | 27 (30.3) | 38 (34.2)g | 34 (39.1) | 36 (49.3)a |
Antiplatelet agents, n (%) | 46 (51.7) | 78 (70.3)bd | 50 (57.5)g | 57 (78.1)be |
Statins, n (%) | 28 (31.5) | 59 (53.2)bd | 31 (35.6)g | 39 (53.4)be |
- Citation: Korbut AI, Klimontov VV, Vinogradov IV, Romanov VV. Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes. World J Diabetes 2019; 10(11): 517-533
- URL: https://www.wjgnet.com/1948-9358/full/v10/i11/517.htm
- DOI: https://dx.doi.org/10.4239/wjd.v10.i11.517